Communiqués TIGENIXADR Nasdaq

Actions

TIG

US88675R1095

Temps Différé Nasdaq Varia. 5j. Varia. 1 janv.
- USD -.--% Graphique intraday de TIGENIXADR -.--% -

Communiqués

18/08/20 AM Best : Assigns Issuer Credit Rating to Trean Insurance Group, Inc.; Affirms Credit Ratings of Benchmark Insurance Group Members BU
21/07/20 Trean Insurance Group Announces Closing of Initial Public Offering GL
16/07/20 Trean Insurance Group Prices Initial Public Offering GL
31/07/18 Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period GL
06/07/18 TIGENIXADR : Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq... BU
06/07/18 TIGENIXADR : Takeda et TiGenix annoncent les résultats de la deuxième période d’acceptation pour l’offre publique d’acquisition volontaire et conditionnelle de TiGenix, le début du retrait simplifié et son intention de radier les ADS du Nasdaq... BU
14/06/18 Transparency notification pursuant to Article 14 of the Law of May 2, 2007 GL
08/05/18 TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018 GL
15/12/17 Takeda : and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease BU
24/11/17 JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix GL
31/10/17 TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure GL
10/05/17 TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York GL
Aucun résultat pour cette recherche